Insmed to Present at Three September Conferences

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.

BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:

• The H.C. Wainwright Annual Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET
   
• The Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 9:30 a.m. ET
   
• The Cantor Virtual Healthcare Conference on Thursday, September 17, 2020 at 9:20 a.m. ET

Each presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com 

Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-three-september-conferences-301126868.html

SOURCE Insmed Incorporated

FAQ

What conferences will Insmed present at in September 2020?

Insmed will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, the Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020.

How can I access the Insmed presentations from the conferences?

The presentations can be accessed live through the investor relations section of Insmed's website and will be archived for 30 days after the events.

What is the significance of ARIKAYCE® by Insmed?

ARIKAYCE® is the first therapy approved in the U.S. for treating refractory Mycobacterium avium complex lung disease, providing essential options for patients with limited alternatives.

What is the ticker symbol for Insmed?

The ticker symbol for Insmed is INSM.

What is the date and time for Insmed's presentation at the H.C. Wainwright Conference?

Insmed's presentation at the H.C. Wainwright Annual Global Investment Conference is scheduled for September 14, 2020, at 9:30 a.m. ET.